Children face over twice the risk of paediatric long COVID after SARS-CoV-2 reinfection, highlighting urgent needs for ...

Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved ...

Increases in type I interferon and antigen-presenting cell activation were seen in association with SARS-CoV-2 mRNA vaccination in humans, and increased PD-L1 expression was seen on tumor biopsies ...

Children and adolescents demonstrated an increased risk for long COVID following SARS-CoV-2 reinfection during the Omicron period.

A study presented at the annual European Society of Medical Oncology Congress 2025 and published in the journal Annals of ...

In this cohort study of patients infected with COVID-19, patients with serious mental illness (schizophrenia, bipolar disorder, or ...

Largely ignored by governments and trade unions, the SARS-CoV-2 XFG variant has, in a short time, become the dominant variant ...

A new way to deliver protective antibodies against COVID-19 was tested in a Phase I clinical trial. Instead of injecting ...

About 32.5% of pediatric patients experienced long COVID symptoms lasting more than 1 year following acute COVID-19 infection.

A USA cohort study finds persistent olfactory dysfunction up to 2 years after COVID-19, even in people unaware of smell loss.

The Covid-19 mRNA-based vaccines that saved 2.5 million lives globally in the pandemic could help spark the immune system to ...

The BRZ batCoV virus, carrying a Covid-19-like feature, broadens the range of batborne viruses that can jump species.